# A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

Source: https://onco.cc/trials/nct07099430/  
OnCo record `nct07099430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. is a phase 1/2 interventional study registered as NCT07099430 by Nanjing Leads Biolabs Co.,Ltd, with 280 participants planned, started 2025-09-05. Conditions recorded: Advanced Melanoma. Interventions recorded: LBL-024 for Injection and Toripalimab Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07099430
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT07099430: https://clinicaltrials.gov/study/NCT07099430

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Opamtistomig](https://onco.cc/drugs/opamtistomig/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct07099430.json